Top Markets
Coin of the day
Yumanity Therapeutics, Inc. Yumanity Therapeutics, Inc.

Yumanity Therapeutics, Inc.

YMTX
株式のランク #28846
Yumanity Therapeutics Inc. operates as a clinical-stage biopharmaceutical... Yumanity Therapeutics Inc. operates as a clinical-stage biopharmaceutical company. Its primary focus lies in the investigation and development of therapeutic solutions for neurodegenerative conditions, particularly those driven by protein misfolding. The firm aims to discover disease-modifying treatments for a range of neurodegenerative disorders, including Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, amyotrophic lateral sclerosis (ALS), and frontotemporal lobar degeneration. Central to its pipeline is YTX-7739, an innovative small molecule presently in Phase I clinical trials for Parkinson's disease and associated α-synuclein disorders. Additionally, YTX-9184 is undergoing preclinical studies with the goal of treating diverse neurological conditions. The company maintains a license and research collaboration agreement with Merck Sharp & Dohme Corp. Founded in 2014, Yumanity Therapeutics Inc. is headquartered in Boston, Massachusetts.
株価
$1.89
最終同期: 2022-12-16
時価総額
$24.38M
変化(1日)
8.62%
変化(1年)
0.00%
US
取引 Yumanity Therapeutics, Inc. (YMTX)

カテゴリー

Yumanity Therapeutics, Inc.(YMTX)の配当利回りの履歴
Yumanity Therapeutics, Inc.(銘柄コード: YMTX)の配当利回り(TTM)は2026時点で0です。
過去5年間の平均配当利回り: 0.00%
Yumanity Therapeutics, Inc.(YMTX)の2026から2026までの配当利回りの履歴
各年末時点の配当利回り(TTM)
配当利回り 変化
提供された日付のデータは十分ではありません。
類似企業または競合他社の配当利回り(TTM)